Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

8.93
+0.01000.11%
Post-market: 8.90-0.0300-0.34%19:30 EDT
Volume:763.53K
Turnover:6.81M
Market Cap:633.21M
PE:-7.15
High:9.05
Open:8.84
Low:8.78
Close:8.92
52wk High:11.45
52wk Low:4.50
Shares:70.91M
Float Shares:67.62M
Volume Ratio:0.64
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.47
PE(LYR):-5.65

Loading ...

Sagimet Reports 52-Week Phase 3 Open-Label Extension Data Showing 56.7% IGA Success for Denifanstat in Moderate to Severe Acne

Reuters
·
Sep 30

Sagimet Biosciences - Denifanstat Well-Tolerated over 52 Weeks with no Serious Adverse Events

THOMSON REUTERS
·
Sep 30

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at Eadv 2026

THOMSON REUTERS
·
Sep 30

Sagimet Biosciences Schedules Virtual KOL Event on Denifanstat Acne Program

Reuters
·
Sep 28

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Sep 28

Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts

TIPRANKS
·
Sep 26

Sagimet Biosciences Down over 15%, on Pace for Largest Percent Decrease Since April 2025

Dow Jones
·
Sep 25

Sagimet Biosciences Price Target Announced at $7.00/Share by Goldman Sachs

Dow Jones
·
Sep 24

H.C. Wainwright Remains a Buy on Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Sep 22

Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8

MT Newswires Live
·
Sep 09

Sagimet Biosciences Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 09

Sagimet Biosciences initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Sep 09

Sagimet Biosciences Inc. : Barclays Raises to Overweight from Equal-Weight; Raises Target Price to $18 from $8

THOMSON REUTERS
·
Sep 09

Sagimet Biosciences to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 02

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 25

Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained

TIPRANKS
·
Aug 25

Sagimet Biosciences advances AURORA clinical trial

TIPRANKS
·
Aug 25

Sagimet Advances Aurora Phase 3 Acne Trial of Denifanstat, Targets Q4 2026 Enrollment

Reuters
·
Aug 25

Sagimet Biosciences Advances Aurora U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

THOMSON REUTERS
·
Aug 25